TrialArthritis & rheumatology (Hoboken, N.J.)2022

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.

Laura C Coates et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.